STAT3-IN-13 is a potent STAT3 inhibitor.STAT3-IN-13 has antiproliferative and anticancer activity and acts by binding to the structural domain of STAT3 SH2.STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705, which induces apoptosis and inhibits tumor cell growth and metastasis.STAT3-IN-13 can be used to study breast cancer and liver cancer. The study of breast cancer and hepatocellular carcinoma.

143B cells:0.25 μM, STAT3:0.96 μM (Kd), HOS cells:0.11 μM, MG-63 cells:0.55 μM

STAT3-IN-13 (compound 6f), over a period of 48 hours, demonstrates anti-proliferative activity with IC50 values of 0.25, 0.11, and 0.55 μM for 143B, HOS, and MG63 cells, respectively [1].In the concentration range of 0.001-100 μM, STAT3-IN-13 (compound 6f) binds to STAT3 and interacts with STAT3^586-685 in a concentration-dependent manner, with a KD of 0.96 μM [1].Over a period of 24 hours at concentrations ranging from 0 to 1.0 μM in 143B and HOS cells, STAT3-IN-13 (compound 6f) inhibits STAT3 Y705 phosphorylation and suppresses STAT3 in tumor cells [1].At concentrations ranging from 0 to 1.0 μM over 48 hours in 143B cells, STAT3-IN-13 (compound 6f) induces apoptosis in a dose-dependent manner [1].

In vivo, STAT3-IN-13 (compound 6f), administered intraperitoneally at doses of 10-20 mg/kg twice daily for 4 weeks in nude mice, effectively blocks osteosarcoma growth and metastasis [1].